U.S. STERILE INJECTABLES MARKET ANALYSIS

U.S. Sterile Injectables Market, By Molecule Type (Large Molecule and Small Molecule), By Drug Type (Monoclonal Antibody (mAbs), Cytokines, Insulin, Peptide Hormones, Vaccines, and Others), By Therapeutic Application (Cancer, Metabolic Disorder, Cardiovascular Diseases, Infectious Diseases, Musculoskeletal Disorders, and Others), By Route of Administration (Subcutaneous, Intravenous, Intramuscular, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies)

On June 26, 2024, Sharp Services, a global leader in clinical supply chain services and contract pharmaceutical packaging, announced its expansion in Pennsylvania, U.S. This initiative aims to enhance the production capacity for secondary packaging of sterile injectables, responding to the growing demand in the market.
On April 11, 2024, Baxter, a global leader in injectables, anesthesia, and drug compounding, announced the expansion of its pharmaceuticals portfolio with five new injectable product launches in the U.S. These include Norepinephrine Bitartrate in 5% Dextrose Injection, Vasopressin in 0.9% Sodium Chloride Injection, and Vancomycin Injection in new strengths, among others.
In June 2023, Hikma Pharmaceuticals PLC, a global pharmaceutical company, announced the launch of Dobutamine Injection, USP, in a 250 mg/20 mL vial in the U.S. This product is indicated for short-term inotropic support in adults facing cardiac decompensation due to reduced contractility from organic heart disease or surgical procedures.